Press Releases

Month Year

Nov 3, 2020

Sanofi's factory of the future named world's best overall facility by International Society for Pharmaceutical Engineering

* Award recognizes innovative accomplishments in facility design, construction, and operation that are setting the standard for pharmaceutical facilities of the future
Oct 27, 2020

Olipudase alfa demonstrated significant improvement in lung function and spleen volume in patients with ASMD

Results of two clinical studies in adults and children with acid sphingomyelinase deficiency (ASMD) presented at the American Society of Human Genetics 2020 Virtual Meeting
- Photos 2
Oct 26, 2020

Dupixent® (dupilumab) late-breaking pivotal data showing significant improvement in eosinophilic esophagitis signs and symptoms presented for the first time at scientific meetings

- First Phase 3 trial in eosinophilic esophagitis (EoE) to show a biologic medicine significantly improved structural and histologic measures, while rapidly improving ability to swallow in patients 12 years and older
Oct 21, 2020

Sanofi and the Parkinson's Foundation collaborate to advance the availability of free genetic testing and counseling for people with Parkinson's disease

* $1 million in research funding to support PD GENEration, a first-of-its-kind national study offering free genetic testing and counseling for people with Parkinson's disease (PD)
Oct 20, 2020

Sanofi and Merck to present three new studies highlighting combination pediatric vaccines at IDWeek 2020
Oct 13, 2020

Dupixent® (dupilumab) significantly reduced severe asthma attacks in children and is the only biologic to demonstrate improvement in children’s lung function in a randomized Phase 3 trial

Data in children aged 6-11 further suggest Dupixent has potential to be best-in-class treatment option
Sep 21, 2020

Late-breaking ESMO presentation shows Libtayo® (cemiplimab) monotherapy increases overall survival in first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%

In the overall trial population, Libtayo reduced risk of death by 32% compared to chemotherapy
Sep 18, 2020

Positive pivotal data for Libtayo® (cemiplimab) monotherapy in locally advanced basal cell carcinoma featured as a late-breaking presentation at ESMO

Libtayo is the first investigational medicine to show a clinical benefit in advanced basal cell carcinoma following treatment with a hedgehog inhibitor in a prospective trial
Sep 14, 2020

FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

* Designation based on positive results from Part A of pivotal Phase 3 trial
Sep 10, 2020

New England Journal of Medicine publishes positive final results from Phase 1/2a study of BIVV001 in people with severe hemophilia A

BIVV001 is the first investigational factor VIII therapy independent of von Willebrand Factor and has the potential to transform replacement therapy for people with hemophilia A

Show per page

Print
Email page
RSS